Forbion et al. in $196m round for NewAmsterdam Pharma
Forbion, Morningside Ventures and Ascendant BioCapital have led a $196m series-A funding round for Dutch clinical-stage biotechnology company NewAmsterdam Pharma (NAP).
More on Early-stage
Global PayTech Ventures invests €4m in Subaio
Deal is Global PayTech’s first investment and will help Subaio expand into new European markets
Hiro Capital invests $15m in three gaming studios
Funding will help the studios expand their development pipelines and accelerate global growth
Left Lane Capital leads €8.2m series A for Memmo.me
Swedish platform allows users to request personalised video messages from celebrities
Midroc New Technology leads €9m round for CorPower Ocean
Wave energy startup has so far raised €38m in equity and public investments
Latest News
Agilitas 2020 Private Equity closes on €565m
Fund focuses on mid-market companies across western Europe, within a range of sectors
Apax sells Sandaya to InfraVia
Sale ends a five-year holding period for Apax, which acquired a majority stake in Sandaya from Pragma Capital
CapMan Special Situations acquires HopLop
HopLop is the first investment from the GP's newly launched special situations strategy
Paragon sells NovumIP to GP-backed Questel
Transaction will see Paragon invest in Questel for a minority stake in the IP consultancy firm